Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling

Abstract

SAA combined with CRP might be used as prognostic serological biomarkers in early-stage melanoma patients, helping to discriminate low-risk patients from high-risk patients needing adjuvant treatment.